Stifel analyst Paul Matteis raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $83 from $77 and keeps a Hold rating on the shares after the company announced it will be lowering the annual wholesale acquisition cost of Tryngolza to $40,000 for FCS, which will be maintained for the sHTG upon approval expected in June. The $40,000 WAC is above expectations, but “probably more like ~20-25% above,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $120 from $110 at H.C. Wainwright
- Ionis announces NDA for zilganersen accepted by U.S. FDA for Priority Review
- Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS
- Ionis Pharmaceuticals Announces Board Retirements and New Appointment
- Ionis Pharmaceuticals price target raised to $100 from $87 at Piper Sandler